# AbolerIS Pharma: Research, Charleroi, Belgium

> AbolerIS Pharma: AbolerIS Pharma is a Belgian clinical-stage biopharmaceutical company founded in November 2019. Based in Charleroi, Belgium. Founded 2019.

Source: https://millionrounds.com/startup/aboleris-pharma (Millionrounds; every figure on the page links to its filing or article)

Belgium · [Research startup](https://millionrounds.com/companies)

# AbolerIS Pharma

AbolerIS Pharma is a Belgian clinical-stage biopharmaceutical company founded in November 2019.

Funding reported Last round: Series A

Research Charleroi, Belgium

Company summary

- **Founded:** 2019 7 years old
- **Team:** 13 11 to 50 people
- **Funding reported:** 29.8M as listed, currency not stated
- **Last round:** Series A Sept 2023

How sure we are

- ✓ **Listed** We know it exists and what it does
- 2 **Funding reported** A company dataset reports a raise
- 3 **Observed** A filing or a dated announcement confirms a round

No round for AbolerIS Pharma has been confirmed by a filing or an announcement yet, so nothing here counts toward an investor's record. [How we decide](https://millionrounds.com/methodology)

## About AbolerIS Pharma

AbolerIS Pharma is a Belgian clinical-stage biopharmaceutical company founded in November 2019.

The company develops novel immunomodulatory therapies aimed at restoring immune tolerance for patients with chronic autoimmune and inflammatory diseases. It was established by three prominent scientists: Dr. Carole Guillonneau, Dr. Ignacio Anegon, and Dr. François-Xavier Hubert, who are all affiliated with the Nantes University Hospital in France. The company is currently conducting Phase 1 studies, with its lead product, ABO21009, a humanized monoclonal antibody targeting CD45RC. This therapy is designed to deplete effector T cells while preserving regulatory and memory T cells, primarily targeting conditions such as Rheumatoid Arthritis, Inflammatory Bowel Disease, and organ transplantation. AbolerIS Pharma also focuses on a secondary strategy involving IL-34 cytokine to induce tolerogenic macrophages and regulatory T cells, addressing chronic autoimmune and inflammatory conditions. The company aims to provide innovative solutions for patients with unmet medical needs in these areas.

## What company datasets say AbolerIS Pharma raised

Funding, as reported

Reported in all **29.8M** in the source's currency

Rounds **2**

Last round **Series A**

Last round size **30M**

Last round date **Sept 2023**

Investors listed **8**

## Founders and team

From AbolerIS Pharma's own website: 5 on the team.

- **Philippe Alen** Chief Business Officer (ad intrim)
- **Tomas Van Dyck** CFO
- **Antoine Thomas** Head of CMC
- **Benoit Moreaux** Head of Operations
- **Professor Michel Goldman** Board of Directors

## On 3 portfolio pages

Investors who name them

- [Newton Biocapital](https://millionrounds.com/fund/newton-biocapital)
- [Criteria Bio Ventures](https://millionrounds.com/fund/criteria-bio-ventures)
- [SFPIM](https://millionrounds.com/fund/sfpim)

Each firm lists AbolerIS Pharma on its own website. That is the firm's claim, a weaker thing than a round we watched, but a named source.

## The company, in detail

What they build

Known for

autoimmune disease research hospital & health care health care autoimmune and inflammatory disorders autoimmune disease biotech startup firm autoimmune disease biotech medical autoimmune diseases treatment immune system regulation immune tolerance biotechnology research healthcare autoimmune disease biotech company autoimmune disease biotech startup company autoimmune disease health

Built with from their website

Yoast Yoast SEO Google Analytics Microsoft Email Providers Contact Form 7 Cloudflare Rocket Loader Priority Hints CAPTCHA Google Font API Drupal

+8 more

Open Graph IONOS WordPress.org imagesLoaded Microsoft Exchange jQuery Microsoft 365 RSS

- **Sector:** Research
- **Industry code:** NAICS 541714, SIC 2834
- **Region:** Region Wallonne
- **Revenue:** 1M a year, as listed
- **Full record:** [Every detail in the company directory](https://millionrounds.com/directory/aboleris-pharma)

## Research in Belgium

Startups like it

- [**Fyteko** Anderlecht · founded 2014 *Raised*](https://millionrounds.com/company/fyteko)
- [**Cellaïon** Mont-Saint-Guibert · founded 2021](https://millionrounds.com/startup/cella-on)
- [**Precirix** Jette · founded 2014](https://millionrounds.com/startup/precirix)
- [**Full-Life Technologies** Gembloux · founded 2021](https://millionrounds.com/startup/full-life-technologies)
- [**Augustine Therapeutics** Leuven · founded 2019](https://millionrounds.com/startup/augustine-therapeutics)
- [**NOVADIP Biosciences S.A.** Mont-Saint-Guibert · founded 2013](https://millionrounds.com/startup/novadip-biosciences-s-a)
- [**EyeD Pharma** Seraing · founded 2012](https://millionrounds.com/startup/eyed-pharma)
- [**atbtherapeutics** Marche-en-Famenne · founded 2018](https://millionrounds.com/startup/atbtherapeutics)

## Is this your company?

Add your raise, your deck and your story, and put AbolerIS Pharma in front of investors. Or tell us what we have wrong.

[List your startup](https://millionrounds.com/list-your-startup)[Send a correction](https://millionrounds.com/corrections)